Improving the assessment of the probability of success in late stage drug development.

Hampson, Lisa V; Bornkamp, Björn; Holzhauer, Björn; Kahn, Joseph; Lange, Markus R; Luo, Wen-Lin; Cioppa, Giovanni Della; Stott, Kelvin; Ballerstedt, Steffen

Hampson, Lisa V; Bornkamp, Björn; Holzhauer, Björn; Kahn, Joseph; Lange, Markus R; Luo, Wen-Lin; Cioppa, Giovanni Della; Stott, Kelvin; Ballerstedt, Steffen.

Afiliação

Hampson LV; Analytics, Novartis Pharma AG, Basel, Switzerland.
Bornkamp B; Analytics, Novartis Pharma AG, Basel, Switzerland.
Holzhauer B; Analytics, Novartis Pharma AG, Basel, Switzerland.
Kahn J; Analytics, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Lange MR; Analytics, Novartis Pharma AG, Basel, Switzerland.
Luo WL; Analytics, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Cioppa GD; Clinical R&D Consultants srl, Rome, Italy.
Stott K; Portfolio Analytics, Novartis Pharma AG, Basel, Switzerland.
Ballerstedt S; Analytics, Novartis Pharma AG, Basel, Switzerland.

Pharm Stat ; 21(2): 439-459, 2022 03.

Article em En | MEDLINE | ID: mdl-34907654

Assuntos

Desenvolvimento de Medicamentos; Projetos de Pesquisa; Teorema de Bayes; Desenvolvimento de Medicamentos/métodos; Humanos; Probabilidade

Palavras-chave

Bayesian methods; expert elicitation; meta-analysis; quantitative decision making

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa / Desenvolvimento de Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Pharm Stat Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google